{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:03:26Z","timestamp":1788393806681,"version":"build-2803163510"},"reference-count":16,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"manuscript writing was sponsored by Takeda Pharmaceuticals USA, Inc. Lexington, Massachusetts, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2023,2,7]]},"DOI":"10.1080\/14737167.2023.2160705","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:53:21Z","timestamp":1671540801000},"page":"225-230","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-4576","authenticated-orcid":false,"given":"Michael","family":"Bullano","sequence":"first","affiliation":[{"name":"U.S Medical Office, Health Economics and Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0086-3474","authenticated-orcid":false,"given":"Christina","family":"Cool","sequence":"additional","affiliation":[{"name":"Precision Value and Health, New York, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-8378","authenticated-orcid":false,"given":"Bob G.","family":"Schultz","sequence":"additional","affiliation":[{"name":"U.S Medical Office, Health Economics and Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Durgapal","sequence":"additional","affiliation":[{"name":"Precision Value and Health, New York, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-4385","authenticated-orcid":false,"given":"Naomi","family":"Sacks","sequence":"additional","affiliation":[{"name":"Precision Value and Health, New York, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Liu","sequence":"additional","affiliation":[{"name":"Precision Value and Health, New York, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kee","sequence":"additional","affiliation":[{"name":"Precision Value and Health, New York, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3672-8741","authenticated-orcid":false,"given":"Katharine","family":"Batt","sequence":"additional","affiliation":[{"name":"Precision Value and Health, New York, CA, USA"},{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001743"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24777"},{"key":"cit0004","unstructured":"National Hemophilia Foundation. Products Licensed in the US. 2021. [cited 2021 1 November]. Available from: https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/products-licensed-in-the-us#5."},{"key":"cit0005","unstructured":"United States Food and Drug Administration. Prescribing Information NovoSeven\u00ae RT, Coagulation Factor VIIa (Recombinant). 2014 [cited 2022]; Available from: https:\/\/www.fda.gov\/media\/70442\/download."},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002977"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.2217\/frd-2022-0005"},{"key":"cit0008","volume-title":"Historical Impact Files for FY 1994 through present","author":"Centers for Medicare & Medicaid Services","year":"2021"},{"key":"cit0009","unstructured":"Centers for Medicare & Medicaid Services. Medicare provider cost report public use files. 2022; Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Cost-Report."},{"key":"cit0010","volume-title":"Medicare claims processing manual chapter 3-inpatient hospital billing","author":"Centers for Medicare & Medicaid Services","year":"2021"},{"key":"cit0011","unstructured":"Asper F Calculating \u201cCost\u201d: cost-to-Charge Ratios. cited 2021; Available from: http:\/\/resdac.umn.edu\/sites\/resdac.umn.edu\/files\/Calculating%20Cost%20-%20Cost-to-Charge%20Ratios%20(Slides).pdf."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.0146"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13592"},{"key":"cit0014","unstructured":"National Organization for Rare Disorders. Acquired Hemophilia. 2016 [cited 2021 31 Jun]. Available from: https:\/\/rarediseases.org\/rare-diseases\/acquired-hemophilia\/."},{"key":"cit0015","unstructured":"National Organization for Rare Disorders. Hemophilia A. 2015 [cited 2021 31 Jun]. Available from: https:\/\/rarediseases.org\/rare-diseases\/hemophilia-a\/."},{"issue":"10","key":"cit0016","first-page":"85","volume":"15","author":"Mustafa M","year":"2016","journal-title":"ISOR J Dent Med"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2160705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T13:24:02Z","timestamp":1675171442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2160705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,7]]}},"alternative-id":["10.1080\/14737167.2023.2160705"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2160705","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}